Head-to-Head Evaluation of the Cancer Ontology Supervised Multimodal Orchestration (COSMO) AI System Versus Pathologist-Only Review
This study evaluates the diagnostic performance of the Cancer Ontology Supervised Multimodal Orchestration (COSMO) AI system for cancer subtype classification and compares it head-to-head with pathologist-only review. Pathologists will independently review de-identified whole-slide images derived from up to 300 patients across three anatomical sites (brain, lung, kidney) and provide diagnostic assessments. In parallel, COSMO will process the same cases offline to generate independent predictions, enabling direct comparison of diagnostic accuracy between human experts and the AI system. The study will characterize the diagnostic accuracy of COSMO and pathologists, inter-observer agreement, and variations in performance across anatomical sites and cancer types with different incidence rates. Results will establish how COSMO compares to pathologists on identical cases and will inform the development of AI-assisted diagnostic systems in clinical practice.
Checked against the public recordLast updated Dec 29, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Harvard Medical School (HMS and HSDM)
- Interventions being studied
- Diagnostic Test: Digital Pathology Evaluation
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Board-certified pathologist with expertise in neuropathology, pulmonary pathology, urologic pathology, or general anatomical pathology * Minimum of 3 years of clinical diagnostic experience * Active clinical practice involving diagnostic pathology slide review * Willingness to independently review and diagnose up to 300 de-identified whole-slide images * Ability to access the study platform and complete case reviews within the specified study timeline * Provision of informed consent for study participation Exclusion Criteria: * Prior involvement in the design or validation of the COSMO AI system * Inability to commit sufficient time to complete assigned case reviews * Presence of significant financial conflicts of interest related to the study outcomes
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Harvard Medical SchoolBoston, Massachusetts
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 29, 2025. Always confirm current availability with the study team.